8-K: Theriva Biologics Secures $2.28 Million Funding for THERICEL Project

Theriva Biologics has been awarded $2.28 million in funding from the Spanish government to advance its THERICEL project, a suspension cell platform for manufacturing viral-based therapies.

Summary

• Theriva Biologics has received 2.28 million in funding from the Spanish government's National Knowledge Transfer Program.
• The funding supports a collaboration with the Universitat Autnoma de Barcelona (UAB) to develop a suspension cell platform for manufacturing adenovirus and adeno-associated virus (AAV) therapies.
• Theriva will receive a 1.33 million unsecured loan as a lump sum in Q4 2024, with a 4.015% interest rate, repayable over 7 years after a 3-year grace period.
• UAB will receive a 0.95 million grant for the THERICEL project, paid in annual installments over the next 3 years.
• The THERICEL project aims to establish the viability of Theriva's A549 suspension cell platform for clinical manufacturing of viral therapies.
• The project is expected to increase efficiency and reduce manufacturing costs compared to current adherent cell platforms.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant funding award, which is expected to accelerate the company's research and development efforts. The loan terms are also favorable, with a 3-year grace period before repayments begin.

Positives

• The funding provides additional capital for Theriva's research and development.
• The award validates Theriva's therapeutic approach and technology.
• The project has the potential to significantly reduce the cost of manufacturing viral therapies.
• The collaboration with UAB provides access to additional expertise and resources.
• The funding will accelerate the start-up of Theriva's innovative suspension cell platform.

Negatives

• The 1.33 million is a loan and will need to be repaid with interest.
• The loan repayment will commence after a 3-year grace period and continue for 7 years.
• The project's success is dependent on the viability of the suspension cell platform.

Risks

• The company's ability to successfully utilize the funding is a risk.
• The project's success depends on the ability to scale up the manufacturing of virus and AAV products.
• Clinical milestones may not be reached as anticipated.
• The product candidates may not demonstrate safety and effectiveness.
• Regulatory approval for commercialization may not be obtained.
• Competitors may develop products that render Theriva's products obsolete.

Future Outlook

The company anticipates that the THERICEL project will establish the viability of their suspension cell platform for clinical manufacturing, potentially leading to more efficient and cost-effective production of viral therapies and collaborative opportunities in product manufacture.

Management Comments

• Steven A. Shallcross, CEO of Theriva Biologics, stated that the funding provides additional capital and external validation of their therapeutic approach.
• He also mentioned that the award will accelerate the start-up for their innovative suspension cell platform.

Industry Context

This announcement is relevant to the broader trend of improving manufacturing processes for viral-based therapies, which are increasingly important in gene therapy and oncolytic virus development. The move towards suspension cell platforms is a key area of innovation in the industry.

Comparison to Industry Standards

• The use of suspension cell platforms for viral vector manufacturing is gaining traction as an alternative to traditional adherent cell culture methods.
• Companies like Oxford Biomedica and Brammer Bio are also investing in advanced manufacturing technologies for viral vectors.
• The 2.28 million funding is a significant amount for a project of this nature, but it is not uncommon for companies to seek government grants and loans to support research and development.
• The 4.015% interest rate on the loan is within the typical range for unsecured loans of this type.

Stakeholder Impact

• Shareholders may view this as a positive development, potentially increasing the company's value.
• Employees may benefit from the increased resources and opportunities for growth.
• Customers may benefit from the potential for more efficient and cost-effective therapies.
• Suppliers may see increased demand for their products and services.

Next Steps

• Theriva intends to execute the loan documents upon receipt.
• The company will focus on scaling-up the manufacture of VCN-01 using the suspension cell platform.
• UAB researchers will evaluate the potential of the suspension cell line for AAV product manufacturing.

Key Dates

Keywords

Theriva Biologics, THERICEL, suspension cell platform, viral therapies, adenovirus, AAV, manufacturing, funding, loan, grant, oncolytic virus, VCN-01